Medical Developments International Limited updated shareholders on the randomised, double-blind, multicentre, placebo controlled study to evaluate the safety and efficacy of methoxyflurane (PENTHROX®) for the treatment of acute pain in children and adolescents from 6 to less than 18 years of age (presenting to an Emergency Department with minor trauma). The trial has just conducted its first scheduled Data and Safety Monitoring Board ("DSMB") Review meeting. The DSMB is assigned to oversee the safety and progress of the trial and is a group of independent experts that are not directly involved in recruiting patients into the study, are not employees of the company and do not have any financial interest in the trials.